WVU cancer researcher appointed to NIH grant review committee
MORGANTOWN, W.Va. – Laura F. Gibson, Ph.D., deputy director of the Mary Babb Randolph Cancer Center (MBRCC) and the Alexander B. Osborn Distinguished Professor in Hematological Malignancies Research at West Virginia University, has been appointed as a regular member of the Basic Mechanisms of Cancer Therapeutics (BMCT) study section for the National Institutes of Health (NIH).
The BMCT study section is a federal advisory committee that reviews grant applications from cancer researchers across the country focused on new anti-cancer drugs and causes of tumor cell resistance to therapy. Dr. Gibson will serve a four-year term, during which she will contribute to the evaluation of the scientific merit of proposed research to help determine which is selected for NIH funding.
Gibson was selected for inclusion on the BMCT because of her work in tumor cell resistance to therapy and strategies to circumvent drug resistance, currently funded by the National Cancer Institute (NCI).
“It is always exciting to join colleagues from diverse institutions on study section. You gain insights into the constantly changing scientific expectations and the review process, and it is also a terrific networking opportunity,” said Gibson, who co-leads the Osborn Hematopoietic Malignancy and Transplantation Program.
She has previously served full terms on additional study sections, including Experimental Therapeutics (ET-2) and Tumor Microenvironment (TME), and has reviewed for several special emphasis panels at the NIH.
In addition to her NCI-supported work, Gibson’s lab and her clinical colleagues in the Osborn Program have received more than 15 years of uninterrupted NIH funding from the National Heart Lung and Blood Institute (NHLBI) to study the effects of aggressive chemotherapy treatment prior to bone marrow transplantation. Her lab also receives funding from the St. Baldrick’s Foundation to study how leukemic cells migrate into the central nervous system and how they respond to therapy at that particular site.
Gibson serves as the principal investigator on grants that total over $1 million annually, including Phase-III support provided by the National Center for Research Resources for the MBRCC’s Center of Biomedical Research Excellence (CoBRE) for Signal Transduction and Cancer.
A WVU graduate, Gibson received her Ph.D. from the Department of Genetics and Developmental Biology in the Davis College of Agriculture, Natural Resources and Design and completed a postdoctoral fellowship supported by the Cancer Research Institute.
The BMCT study section is a federal advisory committee that reviews grant applications from cancer researchers across the country focused on new anti-cancer drugs and causes of tumor cell resistance to therapy. Dr. Gibson will serve a four-year term, during which she will contribute to the evaluation of the scientific merit of proposed research to help determine which is selected for NIH funding.
Gibson was selected for inclusion on the BMCT because of her work in tumor cell resistance to therapy and strategies to circumvent drug resistance, currently funded by the National Cancer Institute (NCI).
“It is always exciting to join colleagues from diverse institutions on study section. You gain insights into the constantly changing scientific expectations and the review process, and it is also a terrific networking opportunity,” said Gibson, who co-leads the Osborn Hematopoietic Malignancy and Transplantation Program.
She has previously served full terms on additional study sections, including Experimental Therapeutics (ET-2) and Tumor Microenvironment (TME), and has reviewed for several special emphasis panels at the NIH.
In addition to her NCI-supported work, Gibson’s lab and her clinical colleagues in the Osborn Program have received more than 15 years of uninterrupted NIH funding from the National Heart Lung and Blood Institute (NHLBI) to study the effects of aggressive chemotherapy treatment prior to bone marrow transplantation. Her lab also receives funding from the St. Baldrick’s Foundation to study how leukemic cells migrate into the central nervous system and how they respond to therapy at that particular site.
Gibson serves as the principal investigator on grants that total over $1 million annually, including Phase-III support provided by the National Center for Research Resources for the MBRCC’s Center of Biomedical Research Excellence (CoBRE) for Signal Transduction and Cancer.
A WVU graduate, Gibson received her Ph.D. from the Department of Genetics and Developmental Biology in the Davis College of Agriculture, Natural Resources and Design and completed a postdoctoral fellowship supported by the Cancer Research Institute.